Earnings call BeOne Medicines delivered a strong Q1 2026, with product revenue of $1.5B (up 34% YoY), BRUKINSA sales of $1.1B (up 38% YoY), and net income of $227M. Management raised 2026 revenue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results